http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
-
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
-
Arcutis Appoints Interim Chief Financial Officer (CFO)
-
Arcutis Biotherapeutic (ARQT) and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
-
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
-
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis to Report Second Quarter Financial Results
-
Arcutis Biotherapeutics Inc. (ARQT) Announces ZORYVE Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
-
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis to Present at Upcoming Investor Conference
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis Biotherapeutics (ARQT) Announces Leadership Transition
-
Arcutis Announces Leadership Transition
-
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
-
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
-
Arcutis Biotherapeutics (ARQT) Announces Canadian Approval of ZORYVE Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
-
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
-
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
-
Arcutis to Report First Quarter Financial Results
-
Arcutis to Report First Quarter Financial Results
-
Arcutis Biotherapeutics (ARQT) Announces FDA Acceptance of NDA for Roflumilast Foam
-
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
-
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
-
Arcutis to Present at Upcoming Investor Conference
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis Biotherapeutics (ARQT) Announces New Coverage for ZORYVE Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
-
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
-
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
-
Arcutis Biotherapeutics Inc. (ARQT) Reports Late-Breaking Data from the INTEGUMENT Phase 3 Trials
-
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
-
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
-
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
-
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Arcutis (ARQT) Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
-
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
-
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
-
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
-
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis Biotherapeutics (ARQT) Reports Strong New Phase 2 Data for Roflumilast Cream
-
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
-
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
